(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios
Dialysis Machines, Dialyzers, Infusion Pumps, Nutrition Products, Clinical Care
FRE EPS (Earnings per Share)
FRE Revenue
Description: FRE Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA is a German healthcare company that provides a range of products and services for chronically ill patients through its four main segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The companys diverse portfolio includes dialysis products and services, medical nutrition and technology, hospital management, and healthcare facility services.
Key Performance Indicators (KPIs) for Fresenius include revenue growth, driven by the increasing demand for healthcare services, particularly in the areas of dialysis and hospital care. The companys ability to maintain a strong market position in Europe and expand its presence in emerging markets is crucial. Additionally, Fresenius operational efficiency, measured by metrics such as EBITDA margin, is essential in maintaining profitability. With a market capitalization of approximately €23.9 billion, Fresenius is a significant player in the European healthcare industry.
From a financial perspective, Fresenius valuation multiples, such as the Price-to-Earnings (P/E) ratio of 22.72, indicate a relatively moderate valuation compared to its peers. The forward P/E ratio of 13.93 suggests expected earnings growth. However, the Return on Equity (RoE) of 2.20% is relatively low, indicating potential areas for improvement in capital allocation and profitability. Analyzing these KPIs in conjunction with the companys segmental performance and industry trends can provide valuable insights into Fresenius future prospects.
To further evaluate Fresenius potential, it is essential to examine its competitive positioning within the healthcare industry, its research and development pipeline, and its strategic initiatives to drive growth and improve profitability. By assessing these factors, investors can gain a more comprehensive understanding of the companys strengths, weaknesses, and opportunities for long-term success.
FRE Stock Overview
| Market Cap in USD | 30,737m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception |
FRE Stock Ratings
| Growth Rating | 77.1% |
| Fundamental | 48.3% |
| Dividend Rating | 32.0% |
| Return 12m vs S&P 500 | 18.5% |
| Analyst Rating | - |
FRE Dividends
| Dividend Yield 12m | 2.35% |
| Yield on Cost 5y | 2.77% |
| Annual Growth 5y | -13.95% |
| Payout Consistency | 81.9% |
| Payout Ratio | 31.5% |
FRE Growth Ratios
| Growth Correlation 3m | 71.4% |
| Growth Correlation 12m | 93.4% |
| Growth Correlation 5y | 0.3% |
| CAGR 5y | 32.17% |
| CAGR/Max DD 3y | 1.46 |
| CAGR/Mean DD 3y | 7.10 |
| Sharpe Ratio 12m | 1.17 |
| Alpha | 26.45 |
| Beta | 0.623 |
| Volatility | 21.05% |
| Current Volume | 549k |
| Average Volume 20d | 573.3k |
| Stop Loss | 45.4 (-3.1%) |
| Signal | -0.19 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.12b TTM) > 0 and > 6% of Revenue (6% = 1.33b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -4.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.63% (prev 12.06%; Δ -0.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.21b > Net Income 1.12b (YES >=105%, WARN >=100%) |
| Net Debt (11.63b) to EBITDA (3.33b) ratio: 3.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (569.0m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 25.40% (prev 23.25%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.40% (prev 51.39%; Δ 1.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.83 (EBITDA TTM 3.33b / Interest Expense TTM 379.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.54
| (A) 0.06 = (Total Current Assets 10.88b - Total Current Liabilities 8.30b) / Total Assets 41.32b |
| (B) 0.35 = Retained Earnings (Balance) 14.29b / Total Assets 41.32b |
| (C) 0.05 = EBIT TTM 2.21b / Avg Total Assets 42.42b |
| (D) 0.62 = Book Value of Equity 13.97b / Total Liabilities 22.38b |
| Total Rating: 2.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.26
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 3.40% = 1.70 |
| 3. FCF Margin 5.57% = 1.39 |
| 4. Debt/Equity 0.63 = 2.31 |
| 5. Debt/Ebitda 3.47 = -2.29 |
| 6. ROIC - WACC -1.44% = -1.80 |
| 7. RoE 5.92% = 0.49 |
| 8. Rev. Trend -82.06% = -6.15 |
| 9. EPS Trend 62.41% = 3.12 |
What is the price of FRE shares?
Over the past week, the price has changed by -0.80%, over one month by +1.85%, over three months by +6.55% and over the past year by +40.93%.
Is Fresenius SE & Co. KGaA a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FRE is around 47.14 EUR . This means that FRE is currently overvalued and has a potential downside of 0.6%.
Is FRE a buy, sell or hold?
What are the forecasts/targets for the FRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.6 | 5.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 51.3 | 9.6% |
FRE Fundamental Data Overview
Market Cap EUR = 26.21b (26.21b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.39b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 23.0396
P/E Forward = 13.0039
P/S = 1.1768
P/B = 1.4511
P/EG = 0.3827
Beta = 1.006
Revenue TTM = 22.23b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.33b EUR
Long Term Debt = 9.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.26b EUR (from shortTermDebt, last quarter)
Debt = 11.57b EUR (Calculated: Short Term 2.26b + Long Term 9.31b)
Net Debt = 11.63b EUR (from netDebt column, last quarter)
Enterprise Value = 36.39b EUR (26.21b + Debt 11.57b - CCE 1.39b)
Interest Coverage Ratio = 5.83 (Ebit TTM 2.21b / Interest Expense TTM 379.0m)
FCF Yield = 3.40% (FCF TTM 1.24b / Enterprise Value 36.39b)
FCF Margin = 5.57% (FCF TTM 1.24b / Revenue TTM 22.23b)
Net Margin = 5.06% (Net Income TTM 1.12b / Revenue TTM 22.23b)
Gross Margin = 25.40% ((Revenue TTM 22.23b - Cost of Revenue TTM 16.58b) / Revenue TTM)
Tobins Q-Ratio = 2.61 (Enterprise Value 36.39b / Book Value Of Equity 13.97b)
Interest Expense / Debt = 0.74% (Interest Expense 86.0m / Debt 11.57b)
Taxrate = 37.54% (521.0m / 1.39b)
NOPAT = 1.38b (EBIT 2.21b * (1 - 37.54%))
Current Ratio = 1.31 (Total Current Assets 10.88b / Total Current Liabilities 8.30b)
Debt / Equity = 0.63 (Debt 11.57b / last Quarter total Stockholder Equity 18.28b)
Debt / EBITDA = 3.47 (Net Debt 11.63b / EBITDA 3.33b)
Debt / FCF = 9.35 (Debt 11.57b / FCF TTM 1.24b)
Total Stockholder Equity = 19.01b (last 4 quarters mean)
RoA = 2.72% (Net Income 1.12b, Total Assets 41.32b )
RoE = 5.92% (Net Income TTM 1.12b / Total Stockholder Equity 19.01b)
RoCE = 7.80% (Ebit 2.21b / (Equity 19.01b + L.T.Debt 9.31b))
RoIC = 4.47% (NOPAT 1.38b / Invested Capital 30.88b)
WACC = 5.91% (E(26.21b)/V(37.78b) * Re(8.31%)) + (D(11.57b)/V(37.78b) * Rd(0.74%) * (1-Tc(0.38)))
Shares Correlation 3-Years: 56.95 | Cagr: 0.09%
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.53% ; FCFE base≈2.05b ; Y1≈1.83b ; Y5≈1.56b
Fair Price DCF = 47.58 (DCF Value 26.80b / Shares Outstanding 563.2m; 5y FCF grow -13.08% → 3.0% )
EPS Correlation: 62.41 | EPS CAGR: 10.57% | SUE: 0.78 | # QB: False
Revenue Correlation: -82.06 | Revenue CAGR: -20.42%